In a report released today, Jason McCarthy from Maxim Group initiated coverage with a Buy rating on Entera Bio Ltd (NASDAQ: ENTX) and a price target of $12. The company’s shares closed yesterday at $5.08.
McCarthy said:
“We are initiating coverage of Buy rating and $12 price target. Entera’s drug delivery platform may be broadly applicable to turn injectable drugs into oral agents. Two oral formulations of parathyroid hormone (PTH 1-34) are in development; EB612 for hypoparathyroidism (HPT) and EB613 for osteoporosis.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 10.8% and a 43.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Entera Bio Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $12.
See today’s analyst top recommended stocks >>
Based on Entera Bio Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.78 million. In comparison, last year the company had a GAAP net loss of $2.26 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.
